# A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

> **NCT07121244** · PHASE1 · RECRUITING · sponsor: **Radionetics Oncology** · enrollment: 62 (estimated)

## Conditions studied

- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
- Metastatic Hormone Receptor Positive Breast Cancer

## Interventions

- **DRUG:** 68Ga-R11228
- **DRUG:** 177Lu-R11228

## Key facts

- **NCT ID:** NCT07121244
- **Lead sponsor:** Radionetics Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2033-06-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121244, "A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07121244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*